PressCenter.com  - Free Press Release Distribution Platform
No Result
View All Result
Monday, January 30, 2023
  • Login
  • Register
  • Home
  • Categories
    • Art & Culture
    • Business & Entrepreneurship
    • Economy & Finances
    • Education & Parenting
    • Energy & Environment
    • Government & Politics
    • Health & Beauty
    • Internet & IT
    • Lifestyle & Fashion
    • Media & Social Networks
    • Society & Welfare
    • Sport & Leisure
    • Technology & Science
    • Traffic & Safety
    • Work & Career
  • Countries
    • Belgium
    • Europe
    • France
    • Germany
    • International
    • Luxembourg
    • Netherlands
    • Others
    • Russia
    • UK
  • Service Portal
    • Press Release Distribution
    • My Press Releases
    • Add Press Release – FREE
    • Service Packs
ADD PRESS RELEASE
PressCenter.com  - Free Press Release Distribution Platform
  • Home
  • Categories
    • Art & Culture
    • Business & Entrepreneurship
    • Economy & Finances
    • Education & Parenting
    • Energy & Environment
    • Government & Politics
    • Health & Beauty
    • Internet & IT
    • Lifestyle & Fashion
    • Media & Social Networks
    • Society & Welfare
    • Sport & Leisure
    • Technology & Science
    • Traffic & Safety
    • Work & Career
  • Countries
    • Belgium
    • Europe
    • France
    • Germany
    • International
    • Luxembourg
    • Netherlands
    • Others
    • Russia
    • UK
  • Service Portal
    • Press Release Distribution
    • My Press Releases
    • Add Press Release – FREE
    • Service Packs
No Result
View All Result
PressCenter.com  - Free Press Release Distribution Platform
No Result
View All Result
Home Sources Business & Entrepreneurs

AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease

by PressCenter.com
August 9, 2013
in Business & Entrepreneurs, Categories, Countries, France, Health & Beauty, Sources
0
1.2k
SHARES
2k
VIEWS
Share on FacebookShare on TwitterLinkedIn
ADVERTISEMENT

This broad collaboration focuses on the US, China and all major markets excluding Japan, Europe, the Commonwealth of Independent States, the Middle East and South Africa, which are covered by an existing agreement between FibroGen and Astellas Pharma Inc. The AstraZeneca-FibroGen joint effort will be focused on the development of FG-4592 to treat anaemia in CKD and ESRD, and may be extended to other anaemia indications.

FG-4592 is a small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase. HIF is a protein that responds to oxygen changes in the cellular environment and meets the body’s demands for oxygen by inducing erythropoiesis, the process by which red blood cells are produced. FG-4592 has the potential to address the considerable unmet medical need for an effective treatment for anaemia that offers the convenience of oral administration and an improved safety profile as compared to current standards of care.

At present, treatment options involve a combination of injectable erythropoiesis-stimulating agents (ESAs) and iron supplements. FG-4592 works through the body’s natural oxygen-sensing and response system to help produce red blood cells. This can be compared to the body’s natural response to conditions at high altitude, where oxygen levels are low, which is to produce more red blood cells.

In Phase II clinical studies, FG 4592 met its primary objective of demonstrating anaemia correction in treatment-naïve CKD patients not on dialysis as well as maintenance of haemoglobin levels and anaemia correction in patients on dialysis. FG 4592 has demonstrated this efficacy combined with an acceptable safety profile in clinical trials, and has been shown to achieve anaemia correction in the absence of intravenous iron supplementation.

The companies plan to undertake an extensive FG-4592 phase III development programme for the US, and to initiate phase III trials in China, with anticipated regulatory filings in China in 2015 and in the US in 2017.

ADVERTISEMENT

AstraZeneca will pay FibroGen committed upfront and subsequent non-contingent payments totalling $350 million, as well as potential future development related milestone payments of up to $465 million, and potential future sales related milestone payments in addition to tiered royalty payments on future sales on FG-4592 in the low 20% range. Additional development milestones will be payable for any subsequent indications which the companies choose to pursue. AstraZeneca will be responsible for the US commercialisation of FG-4592, with FibroGen undertaking specified promotional activities in the ESRD segment in this market. The companies will also co-commercialise FG-4592 in China where FibroGen will be responsible for clinical trials, regulatory matters, manufacturing and medical affairs, and AstraZeneca will oversee promotional activities and commercial distribution.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our collaboration with FibroGen on FG-4592 is an important addition to AstraZeneca’s growing late-stage portfolio in cardiovascular and metabolic disease, one of our core therapy areas. We know from our research into complications of renal disease that anaemia continues to be a challenge for patients with chronic kidney disease, due in part to the inconvenience and complexity of existing injectable and intravenous therapies and the safety concerns associated with them. The science behind this compound is compelling. Through our collaboration with FibroGen we aim to offer a first-in-class, convenient treatment option for doctors and patients.”

Thomas B. Neff, Chief Executive Officer, FibroGen, said: “FG-4592 has the potential to offer anaemia patients an oral therapy that provides coordinated erythropoiesis, that increases natural erythropoietin within the normal physiological range, and that is effective without intravenous iron supplementation and without an increased risk for hypertension. We are especially pleased that AstraZeneca will share our commitment to making China the first-to-launch country for FG-4592 and join our effort to bring important innovation in anaemia therapy to CKD and ESRD patients in the US and other countries. This agreement secures proper development and commercialisation resources for FG-4592, and ensures US clinical trial efforts are fully funded.”

Tags: a treatment for anaemiaAstraZenecachronic kidney diseasecommercial distributionend-stage renal diseaseerythropoiesis-stimulating agentsFG-4592FibroGen
ADVERTISEMENT
ADVERTISEMENT
Perenio presents a line of new smart products at ISE 2023 in Barcelona
Business & Entrepreneurship

Perenio presents a line of new smart products at ISE 2023 in Barcelona

by Press Center Editor
January 27, 2023
0

Perenio, an integral part of the ASBIS Group, takes part in ISE 2023, the world’s leading AV and systems integration...

Read more
Air Ambulance Market will Predicted to Grow at a 5% CAGR

Air Ambulance Market will Predicted to Grow at a 5% CAGR

January 27, 2023
Thailand ready to place youth basketball on the international map

Thailand ready to place youth basketball on the international map

January 28, 2023
Upscene releases database developer tool – Database Workbench 6.1.4

Upscene releases database developer tool – Database Workbench 6.1.4

January 26, 2023
KickRummy Launches To Acquire The Growing Billion Dollar Rummy Market

KickRummy Launches To Acquire The Growing Billion Dollar Rummy Market

January 24, 2023
PressCenter.com  – Free Press Release Distribution Platform

PressCenter.com is state-of-the-art Press Release Distribution Platform. PressCenter.com send and track your Press Release using our industry-leading global Media Contacts Database of a million contacts. Your Press Release will reach business news editors and journalists, in targeted sectors and territories or worldwide.

ArabicChinese (Simplified)DutchEnglishFrenchGermanItalianPortugueseRussianSpanish

Policies

  • Terms & Conditions
  • Copyrights
  • Cookies
  • Disclaimer
  • Privacy Policy

Services

  • Home
  • Press Release Distribution
  • Add Press Release – FREE
  • Guidelines
  • Advertisement
  • About Us
  • Contact Our Team

Press Releases by E-Mail

To stay on top of the ever-changing world of business, subscribe now to our newsletters.

*We hate spam as you do.

Categories

© 1998-2023 PressCenter.com - Latest Business News and Press Releases

No Result
View All Result
  • Home
  • Press Release Distribution
  • Add Press Release – FREE
  • Advertisement
  • Contact Our Team
  • Guidelines
  • About Us

© 1998-2023 PressCenter.com - Latest Business News and Press Releases

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In